Co-Authors
This is a "connection" page, showing publications co-authored by Aditya Juloori and Christine Bestvina.
Connection Strength
2.088
-
DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2024 Dec; 25(8):e448-e452.
Score: 0.892
-
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Jun 20; 43(18):2039-2043.
Score: 0.233
-
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. Eur J Cancer. 2024 Sep; 209:114264.
Score: 0.223
-
Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
Score: 0.214
-
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
Score: 0.192
-
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
Score: 0.182
-
Delays in phases of care from identification to treatment of suspicious lung nodules. JTCVS Open. 2025 Apr; 24:451-471.
Score: 0.057
-
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
Score: 0.050
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.046